These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 29901068)
1. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma. Ishikawa C; Senba M; Mori N Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068 [TBL] [Abstract][Full Text] [Related]
2. Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. Ishikawa C; Senba M; Mori N Int J Oncol; 2018 Oct; 53(4):1681-1690. PubMed ID: 30066853 [TBL] [Abstract][Full Text] [Related]
3. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis. Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118 [TBL] [Abstract][Full Text] [Related]
4. Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo. Joel M; Mughal AA; Grieg Z; Murrell W; Palmero S; Mikkelsen B; Fjerdingstad HB; Sandberg CJ; Behnan J; Glover JC; Langmoen IA; Stangeland B Mol Cancer; 2015 Jun; 14():121. PubMed ID: 26081429 [TBL] [Abstract][Full Text] [Related]
5. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth. Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035 [TBL] [Abstract][Full Text] [Related]
6. Targeting PDZ-binding kinase is anti-tumorigenic in novel preclinical models of ACC. Kar A; Zhang Y; Yacob BW; Saeed J; Tompkins KD; Bagby SM; Pitts TM; Somerset H; Leong S; Wierman ME; Kiseljak-Vassiliades K Endocr Relat Cancer; 2019 Oct; 26(10):765-778. PubMed ID: 31325906 [TBL] [Abstract][Full Text] [Related]
7. Butein inhibits NF-κB, AP-1 and Akt activation in adult T-cell leukemia/lymphoma. Ishikawa C; Senba M; Mori N Int J Oncol; 2017 Aug; 51(2):633-643. PubMed ID: 28586006 [TBL] [Abstract][Full Text] [Related]
8. PBK/TOPK Inhibitor Suppresses the Progression of Prolactinomas. Zhu K; Cheng X; Wang S; Zhang H; Zhang Y; Wang X; Chen Y; Wu J Front Endocrinol (Lausanne); 2021; 12():706909. PubMed ID: 35126305 [TBL] [Abstract][Full Text] [Related]
9. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21. Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899 [TBL] [Abstract][Full Text] [Related]
10. Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Nandi A; Tidwell M; Karp J; Rapoport AP Blood Cells Mol Dis; 2004; 32(1):240-5. PubMed ID: 14757441 [TBL] [Abstract][Full Text] [Related]
11. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma. Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655 [TBL] [Abstract][Full Text] [Related]
12. CDK1-mediated mitotic phosphorylation of PBK is involved in cytokinesis and inhibits its oncogenic activity. Stauffer S; Zeng Y; Zhou J; Chen X; Chen Y; Dong J Cell Signal; 2017 Nov; 39():74-83. PubMed ID: 28780319 [TBL] [Abstract][Full Text] [Related]
13. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma. Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965 [TBL] [Abstract][Full Text] [Related]
14. Gossypetin Inhibits Solar-UV Induced Cutaneous Basal Cell Carcinoma Through Direct Inhibiting PBK/TOPK Protein Kinase. Wang L; Zhang Z; Ge R; Zhang J; Liu W; Mou K; Lv S; Mu X Anticancer Agents Med Chem; 2019; 19(8):1029-1036. PubMed ID: 30827262 [TBL] [Abstract][Full Text] [Related]
15. Baicalin suppresses lung cancer growth by targeting PDZ-binding kinase/T-LAK cell-originated protein kinase. Diao X; Yang D; Chen Y; Liu W Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30898980 [TBL] [Abstract][Full Text] [Related]
16. TOPK/PBK promotes cell migration via modulation of the PI3K/PTEN/AKT pathway and is associated with poor prognosis in lung cancer. Shih MC; Chen JY; Wu YC; Jan YH; Yang BM; Lu PJ; Cheng HC; Huang MS; Yang CJ; Hsiao M; Lai JM Oncogene; 2012 May; 31(19):2389-400. PubMed ID: 21996732 [TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic, nuclear, and total PBK/TOPK expression is associated with prognosis in colorectal cancer patients: A retrospective analysis based on immunohistochemistry stain of tissue microarrays. Su TC; Chen CY; Tsai WC; Hsu HT; Yen HH; Sung WW; Chen CJ PLoS One; 2018; 13(10):e0204866. PubMed ID: 30286126 [TBL] [Abstract][Full Text] [Related]
18. Identification of the oncogenic kinase TOPK/PBK as a master mitotic regulator of C2H2 zinc finger proteins. Rizkallah R; Batsomboon P; Dudley GB; Hurt MM Oncotarget; 2015 Jan; 6(3):1446-61. PubMed ID: 25575812 [TBL] [Abstract][Full Text] [Related]
19. PBK/TOPK: A Therapeutic Target Worthy of Attention. Han Z; Li L; Huang Y; Zhao H; Luo Y Cells; 2021 Feb; 10(2):. PubMed ID: 33670114 [TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC. Hinzman CP; Aljehane L; Brown-Clay JD; Kallakury B; Sonahara F; Goel A; Trevino J; Banerjee PP Carcinogenesis; 2018 Dec; 39(12):1548-1559. PubMed ID: 30165468 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]